Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Cingulate opens at $5, IPO priced at $6 per share » 11:13
12/08/21
12/08
11:13
12/08/21
11:13
CING

Cingulate

/

+

Cingulate (CING) priced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
  • 08
    Dec
Syndicate
Cingulate 4.166M share IPO priced at $6.00 » 06:04
12/08/21
12/08
06:04
12/08/21
06:04
CING

Cingulate

/

+

Aegis and Laidlaw acted…

Aegis and Laidlaw acted as joint book running managers for the offering.

ShowHide Related Items >><<
  • 08
    Dec
Over a month ago
Syndicate
Cingulate IPO price range reduced to $8.00-$10.00, shares to 4.4M » 08:23
10/12/21
10/12
08:23
10/12/21
08:23
CING

Cingulate

/

+

Cingulate's IPO deal…

Cingulate's IPO deal range was lowered to $8.00-$10.00 from $10.00-$12.00 and the deal size was trimmed to 4.44M shares from 4.55M shares. Oppenheimer is acting as lead book running manager for the offering.

ShowHide Related Items >><<
  • 08
    Dec
Over a quarter ago
Syndicate
Cingulate files for IPO, seeks to list on Nasdaq under symbol 'CING' » 15:49
09/09/21
09/09
15:49
09/09/21
15:49
CING

Cingulate

/

+

Cingulate Inc. has filed…

Cingulate Inc. has filed with the SEC for an initial public offering and said in the filing it intends to apply for list its common stock on the Nasdaq Capital Market, or Nasdaq, under the symbol "CING." The prospectus in the filing states in part: "We are a clinical stage biopharmaceutical company using our proprietary Precision Timed Release, or PTR, drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. We are initially focusing our efforts on the treatment of Attention Deficit/Hyperactivity Disorder, or ADHD... We are initially targeting the ADHD stimulant-based treatment market, with an estimated US market size of $15.3 billion in 2020... We completed a proof-of-concept trial in human subjects to validate our PTR platform and in October 2020, announced positive results from a Phase 1/2 study of CTx-1301 in ADHD patients establishing tolerability, comparative bioavailability, and dose proportionality of CTx-1301 versus Focalin XR. We plan to initiate Phase 3 trials in the fourth quarter of 2021 for CTx-1301 with results expected in late 2022. Assuming we receive positive clinical results from our pivotal Phase 3 trials for CTx-1301, we plan to submit a new drug application, or NDA, for CTx-1301 using an accelerated approval pathway under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act in the first half of 2023. In addition, we plan to initiate a Phase 1/2 bioavailability study in ADHD patients for CTx-1302 in early 2022 and, if the results from this study are successful, we plan to initiate pivotal Phase 3 clinical trials in all patient segments for CTx-1302 in late 2022 with results expected in early 2024."

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.